HIV and Hepatitis.com Coverage of the
43rd Annual Meeting of the European Association
for the Study of the Liver (EASL 2008)
April 23 - 27, 2008, Milan Italy
Sign up to receive
our twice-weekly
e-Newsletter
The material posted on HIV and Hepatitis.com about EASL 2008 is not approved
by nor is it a part of EASL 2008.

 


 Hepatitis C Articles
Taribavirin Efficacy Similar to Ribavirin in Combination Therapy for Hepatitis C, but with Less Anemia
Natural History of HCV-Related Cirrhosis after Liver Transplantation
Pegylated Interferon plus Ribavirin Is Effective for Patients with HCV-HBV Coinfection
Factors Predicting Relapse in Patients with Genotype 2/3 HCV Treated with Pegylated Interferon plus Ribavirin
Nitazoxanide Added to Standard Therapy Improves Response in Patients with Genotype 4 HCV: STEALTH C-1 Study
Cyclophilin Inhibitor Debio 025 Exhibits Additive Activity against HCV in Combination with Pegylated Interferon
IDEAL Study Finds Higher End-of-treatment Response with Pegasys, but Lower Relapse Rate with PegIntron
HCV Genotype Is the Strongest Predictor of Sustained Virological Response after Retreatment of Hepatitis C Patients: Final Results of EPIC 3
Milk Thistle (Silibinin) Shows Potent Antiviral Activity in Hepatitis C Patients Who Are Non-responders to Pegylated Interferon/Ribavirin
Italian Program Has Similar Success with Split and Whole Liver Transplantation
R7128 Demonstrates Potent Anti-HCV Activity in Combination with Pegylated Interferon/Ribavirin; Ongoing Trial to be Expanded
Large HCV RNA Decrease Reduces Adverse Clinical Outcomes, but Pegylated Interferon Maintenance Adds Little Benefit (HALT-C)
Boceprevir Added to Pegylated Interferon/Ribavirin Increases Sustained Response in Treatment-naive Patients and Some Prior Non-responders
HCV Polymerase Inhibitor R1626 Produces Good Response with Pegylated Interferon/Ribavirin and Has High Barrier to Resistance
Telaprevir plus Pegylated Interferon and Ribavirin Allows Shorter Therapy for Patients with Genotype 1 HCV
Pegylated Interferon Maintenance Demonstrates Benefits for Hepatitis C Patients with Portal Hypertension
 Hepatitis B Articles
Tenofovir May Be More Effective and Less Expensive than Lamivudine (Epivir-HBV) and Adefovir (Hepsera) as First-line Treatment for HBeAg- Chronic Hepatitis B
Lamivudine (Epivir-HBV) plus Adefovir (Hepsera) Is an Effective Regimen for Lamivudine-resistant HBV Patients Who Develop Resistance to Entecavir (Baraclude)
Pegylated Interferon plus Ribavirin Is Effective for Patients with HCV-HBV Coinfection
Entecavir (Baraclude) Produces Greater Decrease in HBV DNA than Adefovir (Hepsera) in Treatment-naive HBeAg+ Patients: 96 Week Data from EARLY Study
Three Years of Continuous Entecavir (Baraclude) in Chinese Patients with Prior Lamivudine (Epivir-HBV) Failure: Studies ETV-056 and ETV-050
Entecavir (Baraclude) Treatment in Japanese Nucleoside-naive Chronic Hepatitis B Patients
R.E.V.E.A.L.-HBV Study Shows Persistently High Hepatitis B Viral Load Raises the Risk of Liver Cancer
Tenofovir (Viread) Is Effective in Chronic Hepatitis B Patients with Prior Nucleoside/nucleotide Experience
Pegasys Demonstrates Continued Benefits for Chronic Hepatitis B Patients at 4 Years
Gilead Announces 72-Week Data from Pivotal Studies of Tenofovir (Viread) for Chronic Hepatitis B
 HIV-HCV and HIV-HBV Coinfection Article
Liver Transplant Outcomes in HIV Positive Patients with Viral Hepatitis
Some HIV-HBV Coinfected Individuals Experience Delayed Response to Tenofovir (Viread)
 LIbrary of Slides and Posters
Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV)
T Berg and others. EASL 2008.
Tenofovir Disoproxil Fumarate (TDF) is Highly Active for Treatment of Chronic Hepatitis B (CHB) in Patients With Cirrhosis
M Buti and others. EASL 2008.
Cost-Effectiveness Simulation Analysis of Tenofovir Disoproxil Fumarate (Tenofovir) in HBeAg Negative Patients with Chronic Hepatitis-B in Italy and France
B Denzi and others. EASL 2008.
Lack Of Infl uence Of Baseline Genotype On Antiviral Response In Subjects With Chronic Hepatitis B Infection Receiving Tenofovir DF 300 MG QD For 1 Year
E Gane and others. EASL 2008.
Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Positive Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 103)
J Heathcote and others. EASL 2008.
Histologic Evidence of Active Liver Injury in Patients with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B and Normal or Minimally Elevated Serum ALT
K Hu and others. EASL 2008.
The Antiviral Response To Tenofovir Disoproxil Fumarate (TDF) is Comparable in Lamivudine (LAM)-Naïve and LAM-Experienced Subjects Treated for Chronic Hepatitis B (CHB)
M Manns and others. EASL 2008.
Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102)
P Marcellin and others. EASL 2008.
Boceprevir (NS3 Protease Inhibitor) Combination Therapy in Non Responders: Phase II Dose Finding Study
E Schiff and others. EASL 2008.
Final Results of the Phase IIIb IDEAL Study (Individualized Dosing Efficacy vs. Flat Dosing to Assess OptimaL PegInterferon Therapy)
M Sulkowski and others. EASL 2008.
Interim Results from HCV SPRINT-1: RVR/EVR from Phase 2 Study of Boceprevir Plus Peginterferon alfa-2b/Ribavirin in Treatment-Naïve Subjects with Genotype-1 CHC
K Lawitz and others. EASL 2008.

Sustained Viral Response Is Dependent On Baseline Characteristics In The Re-treatment Of Previous Interferon/Ribavirin Non-responders: Final Results From The EPIC3 Program
T Poynard and others. EASL 2008.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sponsors